

REFERENCES

- Aberto L, G. B. (2014) 'High tuberculosis burden among people living with HIV in southern Mozambique', *Eur Respir J*, 04, pp. 547–549.
- Ali, M. K. and Karanja, E. (2017) 'Factors associated with tuberculosis treatment outcomes among tuberculosis patients attending tuberculosis treatment centres in 2016-2017 in Mogadishu, Somalia', *Pan African Medical Journal*, 28, pp. 1–14. doi: 10.11604/pamj.2017.28.197.13439.
- Alvarez, M. A. *et al.* (2011) 'Research Priorities for HIV / M . tuberculosis Co-Infection', *Open Access Journal for Infectious Diseases*, pp. 14–20.
- Atif, M. *et al.* (2018) 'Analysis of tuberculosis treatment outcomes among pulmonary tuberculosis patients in Bahawalpur, Pakistan', *BMC Research Notes. BioMed Central*, 11(1), pp. 1–6. doi: 10.1186/s13104-018-3473-8.
- Bonita, R. and Beaglehole, R. (2006) *Basic Epidemiology 2nd Edition*. World Health Organization 2006.
- Centers for Disease Control and Prevention (2005) *Morbidity and Mortality Weekly Report: Screening HIV-Infected Persons services vices, Prevention*.
- Centers for Disease Control and Prevention (2013) *Introduction to the Core Curriculum on Tuberculosis : What the Clinician Should Know - Sixth Edition 2013*. Available at: www.cdc.gov/tb.
- Connolly, L. E. and Edelstein, P. H. *et* (2007) 'Why is long-term therapy required to cure tuberculosis?', *PLoS Medicine*, 4(3), pp. 435–442. doi: 10.1371/journal.pmed.0040120.
- Cunama L, Garcia Beana I, E. (2019) *Costing Guidelines for Tuberculosis Interventions*. Geneva, Switzerland.
- Departemen Kesehatan Republik Indonesia (2011) 'Rencana Aksi Nasional Programmatic Management of Drug resistance Tuberculosis Pengendalian Tuberkulosis Indonesia: 2011-2014', *Kementerian Kesehatan Republik Indonesia*, pp. 6–18.
- Dinas Kesehatan Jawa Timur (2017) *Profil Kesehatan Provinsi Jawa Timur 2017*. Surabaya.
- Dinas Kesehatan Jawa Timur (2018) *Profil Kesehatan Provinsi Jawa Timur Tahun 2018*. Surab.
- Dinas Kesehatan Kota Surabaya (2019) *Profil Kesehatan 2018*. Surabaya.
- Dooley, K. E. and Chaisson, R. E. (2009) 'Tuberculosis and Diabetes mellitus;

- Converge of Two Epidemics', *Lancet Infect Dis*, 9(12), pp. 737–746. doi: 10.1016/S1473-3099(09)70282-8. Tuberculosis.
- Ejeta, E. *et al.* (2018) 'Factors associated with unsuccessful treatment outcome in tuberculosis patients among refugees and their surrounding communities in Gambella Regional State, Ethiopia', *PLoS ONE*, 13(10), pp. 1–15. doi: 10.1371/journal.pone.0205468.
- Gadallah M A, M. A. R. M. and El-Moghazy E, Fawzy M, K. S. K. (2015) 'Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt', *Journal of the Formosan Medical Association*. Elsevier Taiwan LLC, 115(11), pp. 997–1003. doi: 10.1016/j.jfma.2015.10.002.
- Glanz K, Rimer BK, V. (2008) *Health Behavior and Health Education: Theory, Research and Practice Fourth Edition*. Fourth Edi. Jossey-Bass.
- Glanz, K. and Rimer, B. (2005) *Theory at a Glance: A Guide for Health promotion Practice*. Second Edi, U.S. Department of Health and Human Services; national Institutes of Health. Second Edi. doi: 10.1111/j.1360-0443.1989.tb03059.x.
- Glanz, K., Rimer, B. k. and Viswanath, K. (2002) *Health behaviour and Health Education: Theory, Research and Practice 4th Edition*.
- Gunda, D. W. *et al.* (2018) 'Prevalence and risk factors of active TB among Adult HIV Patients Receiving ART in Northwestern Tanzania: A Retrospective Cohort Study', *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2018. doi: 10.1155/2018/1346104.
- Han, X. *et al.* (2011) 'The impact of diabetes on tuberculosis treatment outcomes: evidence based on a cumulative meta-analysis', *International Journal of Diabetes in Developing Countries*, 36(4), pp. 490–507. doi: 10.1007/s13410-016-0514-5.
- Hovhannesian A, B. E. (2012) 'Time to sputum conversion in multidrug-resistant tuberculosis patients in Armenia: retrospective cohort study', *Global Journal of Medicine and Public Health*, 1(3), pp. 24–28.
- Institute of Medicine (2001) *Health and Behavior: The Interplay of Biological, Behavioral and Societal Influences*, Committee on Health and Behavior: Research, Practice, and Policy Board on Neuroscience and Behavioral Health: INSTITUTE OF MEDICINE. Washington DC: National Academy of Sciences.
- International Union against Tuberculosis and Lung disease (2017) *Best practice for the care of patients with Tuberculosis: A guide for low-income countries - Second Edition*.
- Kementerian Kesehatan RI (2010) *The Joint External TB Monitoring Mission (JEMM*

- TB*). Jakarta, Indonesia.
- Kementerian Kesehatan RI (2011) *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta, Indonesia.
- Kementerian Kesehatan RI (2014) *Infodatin AIDS: Pusat data dan Informasi Kementrian Kesehatan RI, Situasi dan analisis HIV AIDS*.
- Kementerian Kesehatan RI (2015) *Panduan Pelaksanaan Program Kolaborasi TB HIV*. Jakarta.
- Kementerian Kesehatan RI (2016) *Peraturan Menteri Kesehatan Republik Indonesia No. 67 tahun 2016 tentang Penanggulangan Tuberkulosis*. Jakarta, Indonesia.
- Kementerian Kesehatan RI (2017) *Data dan Informasi: Profile Kesehatan Indonesia 2017*. Jakarta, Indonesia.
- Kementerian Kesehatan RI (2018) *Indonesia Health Profile, 2017*. Available at: website: <http://www.kemkes.go.id>.
- Keng Tok, P. S. *et al.* (2020) ‘Determinants of unsuccessful treatment outcomes and mortality among tuberculosis patients in Malaysia: A registry-based cohort study’, *PLoS ONE*, 15(4), pp. 1–14. doi: 10.1371/journal.pone.0231986.
- Kumar, A. (2017) ‘Age-stratified tuberculosis treatment outcomes in Zimbabwe: are we paying attention to the most vulnerable?’, *Public Health Action*, 7(3). doi: doi.org/10.5588/pha.16.0125 Setting:
- Lemeshow S, Hosmer DW, Klar J, L. S. (1991) *Adequacy of Sample Size in Health Studies.*, *Biometrics*. doi: 10.2307/2532527.
- Manurung, M. P. F. *et al.* (2018) ‘Factors related to successful treatment of drug-resistance tuberculosis in H. Adam Malik hospital, Medan, Indonesia’, *IOP Conference Series: Earth and Environmental Science*, 125(1). doi: 10.1088/1755-1315/125/1/012148.
- Medicins Sans Frontieres and Partners in Health (2017) *Practical guide for Clinicians, nurses, laboratory technicians and medical auxiliaries*.
- Medicins Sans Frontieres and Partners in Health (2019) *Clinical guidelines - Diagnosis and treatment manual*.
- Melese, A. and Zeleke, B. (2018) ‘Factors associated with poor treatment outcome of tuberculosis in Debre Tabor, northwest Ethiopia’, *BMC Research Notes*. BioMed Central, 11(1), pp. 1–6. doi: 10.1186/s13104-018-3129-8.
- Ministry of Health Republic of Indonesia (2015) ‘Strategic Planning Ministry of Health’, *Ministry of Health RI*, 28(2), pp. 8–9. Available at: [72](http://p2048-</p>
</div>
<div data-bbox=)

www.liberty.edu.ezproxy.liberty.edu:2048/login?url=http://search.proquest.com
.ezproxy.liberty.edu:2048/docview/1352763280?accountid=12085%5Cn.

- Ministry of Health Uganda (2019) *Tuberculosis and Leprosy Case Management Desk Guide*. Kampa.
- Mkhontfo, M. M. (2016) *An Examination of The Distribution of Diabetes Mellitus Among TB Patients with Pulmonary Tuberculosis and Drug Resistant Tuberculosis In The State Of Florida, USA*. University of South Florida.
- Mukhtar, F. and Butt, Z. A. (2018) 'Risk of adverse treatment outcomes among new pulmonary TB patients co-infected with diabetes in Pakistan: A prospective cohort study', *PLoS ONE*, 13(11), pp. 1–11. doi: 10.1371/journal.pone.0207148.
- Muluye, A. B. *et al.* (2018) 'Poor treatment outcomes and its determinants among tuberculosis patients in selected health facilities in East Wollega, Western Ethiopia', *PLoS ONE*, 13(10), pp. 1–15. doi: 10.1371/journal.pone.0206227.
- Nanzaluka, F. H. *et al.* (2019) 'Factors associated with unfavourable tuberculosis treatment outcomes in Lusaka, Zambia, 2015: a secondary analysis of routine surveillance data', *Pan African Medical Journal*, 32, pp. 1–11. doi: 10.11604/pamj.2019.32.159.18472.
- National Cancer Institute (2005) *Theory at a glance: A Guide for Health Promotion Pracice (Second Edition)*. Maryland, United States.
- Nguyen, D. T., Jenkins, H. E. and Graviss, E. A. (2018) 'Prognostic score to predict mortality during TB treatment in TB/HIV co-infected patients', *PLoS ONE*, 13(4), p. 450. doi: 10.1371/journal.pone.0196022.
- Oshi, D. C. *et al.* (2014) 'Profile and treatment outcomes of tuberculosis in the elderly in southeastern Nigeria, 2011-2012', *PLoS ONE*, 9(11), pp. 2011–2012. doi: 10.1371/journal.pone.0111910.
- Pearce, N. (2012) 'Classification of epidemiological study designs', *International Journal of Epidemiology*, 41(2), pp. 393–397. doi: 10.1093/ije/dys049.
- Pefura-Yone, E. W. *et al.* (2017) 'Development and validation of a prognostic score during tuberculosis treatment', *BMC Infectious Diseases*. BMC Infectious Diseases, 17(1), pp. 1–9. doi: 10.1186/s12879-017-2309-9.
- Pusat Data Dan Informasi Kementerian Kesehatan RI (2018a) *InfoDatin: Situasi Umum HIV/AIDS dan Tes HIV*. Jakarta.
- Pusat Data Dan Informasi Kementerian Kesehatan RI (2018b) *Tuberkulosis InfoDatin*. Jakarta, Indonesia. Available at: www.who.int.
- Rachman BE (2018) 'Prevalence of drug-resistant mutation among drug-treated HIV /

- AIDS inpatient in Airlangga University teaching hospital , Surabaya , Indonesia Prevalence of drug-resistant mutation among drug-treated HIV / AIDS inpatient in Airlangga University teaching h', *IOP Conference Series: Earth and Environmental Science*, pp. 0–6.
- Ruslami, R. *et al.* (2010) 'Implications of the global increase of diabetes for tuberculosis control and patient care', *Tropical Medicine and International Health*, 15(11), pp. 1289–1299. doi: 10.1111/j.1365-3156.2010.02625.x.
- Siddiqui, A. N., Khayyam, K. U. and Sharma, M. (2016) 'Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India: A Prospective Study', *BioMed Research International*, 2016(Dm). doi: 10.1155/2016/7273935.
- Stop TB Partnership (2015) *Global Plan to End TB: The Paradigm Shift 2016-2020, Stop TB Partnership*. Available at: http://stoptb.org/assets/documents/global/plan/GlobalPlanToEndTB_TheParadigmShift_2016-2020_%0AStopTBPartnership.pdf.
- Stop TB Partnership (2018) *Key Populations Brief: People Living with HIV, Global Plan to end TB and Key populations*. Geneva, Switzerland. doi: 10.1097/rnj.0000000000000166.
- Tafess, K. *et al.* (2018) 'Treatment outcomes of tuberculosis at Asella Teaching Hospital, Ethiopia: Ten Years' retrospective aggregated data', *Frontiers in Medicine*, 5(FEB), pp. 1–9. doi: 10.3389/fmed.2018.00038.
- TB CARE I (2014) *International Standards for Tuberculosis Care, Edition 3*. The Hague. doi: 10.1016/S0140-6736(47)92237-X.
- Telzak EE, Fazal BA, P. C. (1998) 'Factors Influencing Time to Sputum Conversion Among Patients with Smear-Positive Pulmonary Tuberculosis', *Clinical Infectious Diseases*, 26(3), pp. 776–776. doi: 10.1086/517134.
- Tola, A., Mishore, K. M., *et al.* (2019) 'Treatment Outcome of Tuberculosis and Associated Factors among TB-HIV Co-Infected Patients at Public Hospitals of Harar Town, Eastern Ethiopia. A five-year retrospective study', *BMC Public Health*. BMC Public Health, 19(1), pp. 1–12. doi: 10.1186/s12889-019-7980-x.
- Tola, A., Minshore, K. M., *et al.* (2019) 'Tuberculosis Treatment Outcomes and Associated Factors among TB Patients Attending Public Hospitals in Harar Town, Eastern Ethiopia: A Five-Year Retrospective Study', *Tuberculosis Research and Treatment*, 2019, pp. 1–11. doi: 10.1155/2019/1503219.
- UNAIDS (2018a) 'FACT SHEET JULY 2018: 2017 GLOBAL HIV STATISTICS', (July), pp. 1–5. Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.p

df.

UNAIDS (2018b) 'UNAIDS Data 2018', *Programme on HIV/AIDS*, (2018 reference), pp. 1–248. doi: 978-92-9173-945-5.

UNICEF INDONESIA (2012) *Issue Brief: Responding to HIV and AIDS*. Jakarta, Indonesia. Available at: www.unicef.or.id.

Vidyaraj, C. K. *et al.* (2017) 'Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes', *Journal of Epidemiology and Global Health*. Ministry of Health, Saudi Arabia, 7(4), pp. 289–294. doi: 10.1016/j.jegh.2017.09.002.

Wen *et al.* (2018) 'Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing , China : a retrospective study', *BMC Infectious Diseases*. BMC Infectious Diseases, 18, pp. 1–12.

World Health Organization (2007) *Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: Recommendations for HIV prevalent and resource-constrained settings*. Geneva, Switzerland.

World Health Organization (2010a) *Guidance on ethics of Tuberculosis prevention, care and control*. Geneva, Switzerland.

World Health Organization (2010b) *Multidrug resistant Tuberculosis (MDR-TB) Indicators*, *Journal International Medical Sciences Academy*. Geneva, Switzerland.

World Health Organization (2010c) 'Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings', pp. 1–64.

World Health Organization (2010d) *Treatment of Tuberculosis guidelines - Fourth Edition*. Geneva, Switzerland.

World Health Organization (2011a) *Guidelines for Intensified Tuberculosis case finding and isoniazid preventive therapy for People Living with HIV in Resource constrained settings*, *Stop TB Department and Department of HIV/AIDS*. Geneva, Switzerland. Available at: www.who.int.

World Health Organization (2011b) *World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test; technical and operational 'how-to' practical considerations.*, Geneva, World Health Organization. Available at: www.who.int.

World Health Organization (2012) *WHO policy on collaborative TB / HIV activities Guidelines for national programmes and other stakeholders*. Geneva,

Switzerland. doi: 23586124.

World Health Organization (2014a) *Policy Implementation package for new TB drug introduction*. Geneva, Switzerland.

World Health Organization (2014b) *THE END TB STRATEGY: Global strategy and targets for Tuberculosis prevention, care and control afetr 2015*. Geneva, Switzerland.

World Health Organization (2014c) *Towards Tuberculosis elimination: An action framework for Low Incidence countries*. Geneva.

World Health Organization (2017a) *Global Tuberculosis Report*. Geneva, Switzerland. Available at: www.who.int.

World Health Organization (2017b) *Review of the National Health Sector Response to HIV in the Republic of Indonesia, Joint External TB Monitoring Mission Country Review on HIV Response*. Jakarta.

World Health Organization (2017c) *The Republic of Indonesia Health System Review, World Health Organization*. Available at: <http://apps.who.int/iris/bitstream/10665/254716/1/9789290225164-eng.pdf>.

World Health Organization (2017d) *WHO Report on the Global Tobacco epidemic, 2017: Monitoring tobacco use and prevention policies*. Geneva.

World Health Organization (2018a) *Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis - Second edition*. Geneva, Switzerland.

World Health Organization (2018b) *Global Tuberculosis report*. Geneva, Switzerland.

World Health Organization (2018c) *Global tuberculosis report 2018*. World Health Organization. <http://www.who.int/iris/handle/10665/274453>.

World Health Organization (2018d) *HIV-Associated Tuberculosis*. Geneva, Switzerland.

World Health Organization (2018e) *Indonesia Tuberculosis profile, WHO. Estimates of TB and MDR-TB burden*. Geneva, Switzerland. doi: www.who.int/tb/data.

World Health Organization (2019a) *Global Tuberculosis report 2019*. Geneva, Switzerland.

World Health Organization (2019b) *Multisectorial accountability framework to accelerate progress to end Tuberculosis by 2030*. Geneva, Switzerland. Available at: www.who.int.

World Health Organization (2019c) *Tuberculosis Co- morbidities and risk factors*.

Available at: <https://www.who.int/southeastasia/activities/co-morbidities-tb>
(Accessed: 28 January 2020).

World Health Organization (2019d) *WHO Guidelines on Tuberculosis infection prevention and control - 2019 update, 2019 update*. Geneva, Switzerland. doi: 10.1017/CBO9781107415324.004.

World Health Organization (2020a) *Rapid Communication on forthcoming changes to the programmatic management of tuberculosis preventive treatment*. Geneva, Switzerland. Available at: <http://apps.who.int/bookorders>.

World Health Organization (2020b) *WHO consolidated guidelines on Tuberculosis. Module 1: prevention - Tuberculosis preventive treatment*. Geneva, Switzerland.

World Health Organization (2020c) *WHO Operational handbook on Tuberculosis. Module 1: prevention - Tuberculosis preventive treatment*. Geneva, Switzerland.

World Health Organization Europe (2005) *Management of Tuberculosis and HIV co-infection-Clinical protocol for the WHO, European Region*. Copenhagen, Denmark. Available at: www.euro.who.int.

World Health Organization SEARO (2011) *Tuberculosis control in the South East Asia Region: The regional report 2011*. India.

World Health Organization SEARO (2016a) *Ending TB in the South-East Asia Region, Regional Strategic Plan*. India: World Health Organisation. Available at: <http://apps.who.int/iris/bitstream/handle/10665/250292/9789290225058-eng.pdf?sequence=1&isAllowed=y>.

World Health Organization SEARO (2016b) *Tuberculosis control in the South - East Asia Region Annual report 2016*. India.

World Health Organization SEARO (2018) *Bending the Curve: Keeping our Promise of Ending TB in the South - East Asia Region on time*. India.